Platform Device

MicroTransponder is developing a platform technology for wireless neurostimulation.  The first product being developed is the SAINT^TM unit (Subcutaneous Arrangement of Injectable Neural Transponders).  The SAINT^TM unit eliminates any implantable battery or wires.  It is injectable with a 12-gauge needle in a 30 minute outpatient procedure.   This implanted platform technology will be coupled to an external controller, which can be worn like an armband; and will provide the power and stimulus parameters for the device.  The external controller will be able to interface with a laptop or PDA in order to change the stimulus parameters to better treat the patient's pain profile.

Current treatments for Chronic Pain

Each year over 40 million Americans suffer from chronic pain. They miss over 500 million days of work, and spend billions on doctor visits and treatment. Current pharmaceutical treatments are costly, have negative side effects, and are not effective for large percentages of the patient population.  Over $2.5 billion is spent annually on neurostimulation treatments, which involve implanted batteries and wires.  These devices have significant failure rates.  Almost 50% fail in the first year and 70% by the third year due to wire breakage or migration.  Our device avoids the side effects that accompany drugs while also eliminating the wires that break and cause migration.